Defining The Role for Hormone Therapy in Biochemically Recurrent Prostate Cancer: What Counts as a Win for Patients?
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Biochemically recurrent prostate cancer presents unique challenges. While enzalutamide shows promise, further research is needed on optimal use and patient-centered trial design for hormonal and non-hormonal therapies.
Area Of Science
- Oncology
- Urology
- Clinical Drug Development
Background
- Biochemically recurrent (BCR) prostate cancer is a heterogeneous condition with generally favorable long-term outcomes.
- Hormonal therapies effectively manage micrometastatic and macrometastatic disease but do not offer a cure.
- Current treatment paradigms face unique clinical and drug development challenges.
Purpose Of The Study
- To evaluate clinical and drug development challenges in BCR prostate cancer.
- To appraise current clinical trials and outline future hormonal and non-hormonal treatment options.
- To provide guidance on patient communication and assess patient value in trial design.
Main Methods
- Review of existing literature and clinical trial data for BCR prostate cancer.
- Critical appraisal of trial designs, endpoints, and patient-reported outcomes.
- Analysis of the role of hormonal and non-hormonal therapies in BCR prostate cancer management.
Main Results
- The EMBARK trial suggests a role for enzalutamide in BCR prostate cancer, though optimal usage and study design warrant further discussion.
- Hormonal therapies are effective for disease suppression and management of metastatic disease.
- Ongoing trials explore combining hormonal therapies with metastasis-directed therapies and evaluating non-hormonal alternatives.
Conclusions
- Careful attention to clinical trial design and endpoints is crucial for accurately measuring treatment benefits and trade-offs in BCR prostate cancer.
- Future research should focus on refining risk stratification and developing novel therapeutic strategies.
- Optimizing patient communication and incorporating patient-reported values are essential for advancing BCR prostate cancer care.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
Hormones intricately bind to receptors on the surface or within target cells, initiating a cascade of cellular responses.
Notably, the cellular response can be regulated by altering the number of receptors expressed in the cell. For example, prolonged exposure to elevated hormone levels results in a gradual decline or down-regulation in the number of receptors for that specific hormone on the cell surface. Conversely, in response to low hormone levels, cells may use up-regulation, producing an...
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...